DAWN vs. AGX

Last updated Jun 24, 2026

DAWN (Day One Biopharmaceuticals, Inc.) and AGX (Argan, Inc.) are both stocks. DAWN operates in Biotechnology (Healthcare), while AGX operates in Engineering & Construction (Industrials). At a 0.15 correlation, their price movements are largely independent.

Performance

DAWN vs. AGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Day One Biopharmaceuticals, Inc. (DAWN) and Argan, Inc. (AGX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

DAWN

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

AGX

• 1D: -6.74%
• 1M: 12.25%
• YTD: 135.64%
• 6M: 121.56%
• 1Y: 255.33%
• 3Y*: 170.89%
• 5Y*: 75.91%
• 10Y*: 37.51%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DAWN vs. AGX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAWN Day One Biopharmaceuticals, Inc.	131.01%	-26.44%	-13.22%	-32.16%	27.72%	-32.60%
AGX Argan, Inc.	135.64%	130.61%	198.31%	30.24%	-2.01%	-20.54%

Correlation

The correlation between DAWN and AGX is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (3Y) Calculated over the trailing 3-year period	0.15
Correlation (5Y) Calculated over the trailing 5-year period	0.16
Correlation (All Time) Calculated using the full available price history since May 27, 2021	0.15

Fundamentals

EPS DAWN : -$1.47 AGX : $11.38
PS Ratio DAWN : 16.63 AGX : 10.02
Total Revenue (TTM) DAWN : $133.67M AGX : $1.04B
Gross Profit (TTM) DAWN : $119.56M AGX : $217.93M
EBITDA (TTM) DAWN : -$141.73M AGX : $163.99M

Return for Risk

DAWN vs. AGX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAWN

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

AGX

AGX Risk / Return Rank: 96
AGX Sharpe Ratio Rank: 97
AGX Sortino Ratio Rank: 94
AGX Omega Ratio Rank: 92
AGX Calmar Ratio Rank: 98
AGX Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAWN vs. AGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Argan, Inc. (AGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	DAWN	AGX	Difference
Sharpe ratio: Return per unit of total volatility	—	3.43	—
Sortino ratio: Return per unit of downside risk	—	3.72	—
Omega ratio: Gain probability vs. loss probability	—	1.47	—
Calmar ratio: Return relative to maximum drawdown	—	10.30	—
Martin ratio: Return relative to average drawdown	—	29.33	—

Drawdowns

Drawdown Indicators

	DAWN	AGX	Difference
Max Drawdown Largest peak-to-trough decline	—	-94.37%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-24.96%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-43.75%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-43.75%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-54.61%	—
Current Drawdown Current decline from peak	—	-6.74%	—
Average Drawdown Average peak-to-trough decline	—	-48.30%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	8.75%	—

Volatility

Volatility by Period

	DAWN	AGX	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	20.17%	—
Volatility (6M) Calculated over the trailing 6-month period	—	54.86%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	74.89%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	51.29%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	46.04%	—

Dividends

DAWN vs. AGX - Dividend Comparison

DAWN has not paid dividends to shareholders, while AGX's dividend yield for the trailing twelve months is around 0.25%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AGX Argan, Inc.	0.25%	0.52%	0.93%	2.24%	2.71%	1.94%	7.31%	2.49%	1.98%	4.44%	1.42%	2.16%
DAWN Day One Biopharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

DAWN vs. AGX - Profitability Comparison

The chart below illustrates the profitability comparison between Day One Biopharmaceuticals, Inc. and Argan, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DAWN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Day One Biopharmaceuticals, Inc. reported a gross profit of 35.32M and revenue of 39.80M. Therefore, the gross margin over that period was 88.7%.

AGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a gross profit of 61.11M and revenue of 290.95M. Therefore, the gross margin over that period was 21.0%.

DAWN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Day One Biopharmaceuticals, Inc. reported an operating income of -24.25M and revenue of 39.80M, resulting in an operating margin of -60.9%.

AGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported an operating income of 45.40M and revenue of 290.95M, resulting in an operating margin of 15.6%.

DAWN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Day One Biopharmaceuticals, Inc. reported a net income of -19.73M and revenue of 39.80M, resulting in a net margin of -49.6%.

AGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a net income of 46.06M and revenue of 290.95M, resulting in a net margin of 15.8%.

Frequently Asked Questions

Can I hold both DAWN and AGX in my portfolio?

DAWN and AGX have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.